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http://www.biomedcentral.com/1471-2407/12/477RESEARCH ARTICLE Open AccessGenetic polymorphisms in the osteopontin
promoter increases the risk of distance metastasis
and death in Chinese patients with gastric cancer
Fujun Zhao1,3†, Xiaoyi Chen1†, Tingting Meng3, Bo Hao1, Zhihong Zhang2 and Guoxin Zhang1*Abstract
Background: In vitro and in vivo studies have suggested that osteopontin (OPN) is associated with many types of
cancers. However, no studies have reported the incidence of OPN polymorphisms and the risk of gastric cancer.
The aim of this study was to investigate the association between OPN polymorphisms and gastric cancer in a
Chinese patient population.
Methods: Three genetic variants in the OPN promoter were genotyped using direct sequencing in 200 gastric
cancer patients and 200 gender- and age-matched cancer-free controls. The 4-year survival curve was calculated
using the Kaplan-Meier method and compared using the log-rank test for each single nucleotide polymorphism
(SNP) site. We measured the promoter activity of the -443 T → C polymorphism using a dual luciferase reporter
assay.
Result: For the variant at nt -443 (CC), there was a significant difference between the number of patients with
stage IV and those with stage I gastric cancer (IA + IB; P = 0.014) and between those with stage IV and all other
stages of gastric cancer (IA + IB + II + III; P = 0.02). For the variant at nt -443 (CT), there was a significant difference
between the number of gastric cancer patients with stage IV and those with stage II (P = 0.013). The survival rates
for patients with the C/C genotype were significantly lower than for patients with the other two genotypes
(C/T, T/T). Moreover, significantly higher luciferase activities were observed in the pGL3-C construct compared to
the pGL3-T construct.
Conclusions: This study provides the first evidence that variation at nt -443 in the OPN promoter increases the
potential for gastric cancer metastasis and subsequent death in the Chinese population.
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Gastric adenocarcinoma remains the second leading
cause of cancer-related deaths worldwide, accounting for
738,000 deaths annually [1]. Gastric cancer is the third
most common cancer in China. The development of
gastric cancer is associated predominantly with Helico-
bacter pylori infection [2], but other risk factors include
a diet high in salt, smoking, consumption of pickled
foods, and specific genetic backgrounds [3]. It has been
shown that H. pylori infection is an independent risk* Correspondence: guoxinz@njmu.edu.cn
†Equal contributors
1Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical
University, Nanjing 210029, China
Full list of author information is available at the end of the article
© 2012 Zhao et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfactor that leads to persistent colonization and chronic
inflammation of the gastric mucosa, thereby increasing
the risk of developing peptic ulceration and gastric can-
cer [2,4-6]. However, there are marked inter-individual
differences in the extent of inflammation among persons
with H. pylori infection, and clinical consequences only
develop in a small numbers of gastric cancer cases.
Multifactorial models suggest that the genetic suscepti-
bility due to specific variant alleles in polymorphisms
may affect the outcomes of environmental exposure [7].
Osteopontin (OPN) is a secreted adhesive phosphogly-
coprotein that contains a functional Gly-Arg-Gly-Asp-
Ser cell-binding sequence [8]. The OPN gene has been
mapped to chromosome 4q24-q25, and it has beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic characteristics of patients with
gastric cancer carcinoma and healthy controls
Characteristic No. of patients or controls P
Cases (n) Control (n)
No. 200 200
Age, years > 0.05
Mean 56.29 55.67
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tastasis [9]. OPN has been shown to be expressed
within tumor cells and in the surrounding stroma of
numerous human cancers, such as colon, breast, lung,
stomach, endometrium, and thyroid, providing a link
with malignant invasion [10-13]. Previous studies
showed that OPN is frequently overexpressed in human
gastric cancer [14], and that expression of OPN mRNA
was significantly higher in gastric cancer tissues com-
pared to non-tumor tissues.
Several polymorphisms have been described for the
OPN gene, some of which are associated with oligoarti-
cular (or pauciarticular) juvenile idiopathic arthritis,
nephrolithiasis, and chronic hepatitis C [15-18]. A recent
study [19] reported that patients with a G/G genotype at
nt -156 in the OPN promoter were more frequently
diagnosed with advanced stage (IIIB-IV) non-small cell
lung cancer (NSCLC) than those with other genotypes,
while another report suggested that the OPN poly-
morphism might be the genetic factor for hepatitis B
viral clearance and hepatocellular carcinoma occur-
rence [20].
There are currently no published studies assessing the
relationship between OPN genetic polymorphisms and
the risk of gastric cancer development. Therefore, the
aim of this study was to determine if an association
exists between OPN polymorphisms and the risk of gas-
tric cancer in the Chinese population.
Methods
Subjects From 2005 to 2008, 310 unrelated patients
with gastric cancer (the GC group), were enrolled at the
First Affiliated Hospital of Nanjing Medical University.
All of the patients were ethnic Han Chinese residents
who had histologically confirmed gastric adenocarci-
noma. The control group (the non-GC group) consisted
of a random sample of 591 ethnic Han Chinese from
Jiangsu Province. After giving written informed consent,
all participants were requested to provide a blood
sample. This study was approved by the Ethics Com-
mittee of the First Affiliated of Nanjing Medical Uni-
versity (# 2010-SR-073).
Before sequencing the genotypes in the OPN pro-
moter, we used SPSS v10.0 (SPSS, Inc., Chicago, IL,
USA) software to randomly select 200 GC patients and
gender- and age-match them to 200 randomly selected
controls of the non-GC group. We evaluated all patients
and controls for H. pylori using an indirect solid phase
immunochromatographic (ICM) assay to investigate the
presence of IgG antibodies to H. pylori (Genelabs Diag-
nostics, Singapore). This test method was previously
validated in our lab with an accuracy of 92.3% [21].
Genomic DNA from controls and gastric cancer
patients was extracted from ethylenediaminetetraceticacid (EDTA)-anticoagulated peripheral blood according
to the traditional proteinase K and phenol-chloroform
method, and stored at -70°C.
Analysis of polymorphisms in the OPN regulatory region
The OPN-66, -156(rs17524488), and -443(rs11730582)
variants were genotyped by direct sequencing of the
sense and anti-sense strands following polymerase chain
reaction (PCR) amplification of the promoter regulatory
region -473 to -3 (forward primer 50-CAA GCT ACT
GCA TAC TCG AAA TCA CA-30; reverse primer 50-
ACA ACC AAG CCC TCC CAG AAT TTA-30), as pre-
viously described [19]. PCR was performed using 50 ng
DNA as a template under the following conditions: 95°C
for 10 min, then 36 cycles of 94°C for 30 s, an annealing
nt -443 TT nt -156GG/GG 




Figure 1 Schematic diagram and sequencing data of the OPN promoter. Representative figure for the sequencing analysis on the promoter.
The SNP nt -443 has the following alleles: CC, CT, and TT. There is a small insertion at nt-156, which has three alleles: G/G, G/GG, GG/GG. The SNP
nt -66 has only one allele: TT.
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Table 2 Comparison of OPN promoter between gastric
cancer patients and healthy controls
Controls Patients Gastric cancer
Genotypes n n P LN (+) LN (-) P
-66
TT 200 200 1.00 124 76 1.00
-156
G/G 86 67 1.00 41 25 1.00
G/GG 78 92 0.064 57 36 0.92
GG/GG 36 41 0.18 25 16 0.91
-443
CC 22 15 1.00 8 8 1.00
CT 93 94 0.28 63 33 0.23
TT 85 91 0.22 53 35 0.45
Table 3 The distribution of genotypes for TNM stages in
gastric cancer
The TNMs of gastric cancer
Genotypes IA IB II III IV
-66
TT 38 44 26 52 40
-156
G/G 16 16 13 20 19
G/GG 16 15 15 16 18
GG/GG 7 9 5 9 6
-443
CC 1 2 1 4 14
CT 17 19 19 19 19
TT 14 18 5 19 29
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extension at 72°C for 15 min. After affinity membrane
purification using the QIAquick Gel Extraction kit
(Qiagen, Carlsbad, CA, USA), the PCR products were
subjected to cycle sequencing with the respective
forward and reverse primer using an automated ABI
3100 DNA sequencer by GeneCore Bio Technologies
(Shanghai China).
Luciferase assay with SNP at nucleotide (nt) -443 in the
OPN promoter
The 250 bp fragments of the OPN promoter (from -590
to -340) carrying either the T or C allele were synthe-
sized by Invitrogen and inserted upstream of the firefly
luciferase gene in the pGL3-Enhancer plasmid vector
(Promega, USA) in separate procedures. Each construct
was confirmed by sequencing. A series of OPN
promoter-luciferase reporter constructs were transiently
transfected into the gastric cancer cell lines MKN28
(Shanghai Institute of Digestive Disease) and SGC-7901
(Shanghai Cancer Institute), and transfection was per-
formed with Lipofectamine 2000 Reagent (Invitrogen)
according to the manufacturer’s protocol. The MKN28
and SGC-7901 cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum. The activity of
the different genotype promoters was measured using
the Luciferase Reporter Assay System (Promega, USA).
All experiments were repeated in triplicate.
Statistical analysis
Statistical analysis was performed using SPSS 10.0 soft-
ware. Quantitative variables departing from the normal
distribution, including age, were summarized as mean
and standard deviation (SD). Comparison of age between
cases and controls was assessed using an independent
Student’s t-test. Comparison of extra-gastric tumors,
H. pylori infection, and genotype frequencies between
cases and controls was assessed using a chi-square test and
a Fisher’s exact test. Survival was calculated by the Kaplan-
Meier method. All probability (P) values were two-tailed
and statistical significance was indicated as P < 0.05.
Results
Demographic and clinical features of the patients
The gastric cancer (GC) group consisted of 200 indivi-
duals (64% male), with a mean age of 56.29 ± 3.46 years.
The control (non-GC) group consisted of 200 indivi-
duals, of which 64% were male, with a mean age of
55.67 ± 4.21 years (Table 1). There were no significant
differences in terms of distribution of age and gender as
well as H. pylori seropositivity. Clinicopathologic charac-
teristics of the patients and controls are shown in
Table 1.SNPs in the promoter region of human OPN gene
Direct sequencing of DNA fragments between nt -473
and nt -3 in patients and age- and gender-matched con-
trols revealed 3 SNPs in the OPN promoter, located at
nt -156 [GG/GG homozygotes, GG/G-(deletion) hetero-
zygotes, G-/G- homozygotes], nt -443 [CC homozygotes,
CT heterozygotes, TT homozygotes], and nt -66
(Figure 1), as shown in Table 2. There was no significant
difference in the distribution of these SNPs (nt -66, -156,
-443) between GC patients and controls. The distribu-
tion of genotypes for TNM stages in gastric cancer is
shown in Table 3.
However, regarding tumor-node-metastasis TNM
stages, we found that for the SNP at nt -443, among
patients with the CT genotype, there was a significant
difference between patients with stages II and IV (P <
0.01), and between stage IV and all other stages (IA +
IB + II + III; P = 0.04; Table 4). Similarly, among patients
with the CC genotype at nt -443, there was a significant
difference between patients with stages IV and stage I
Table 4 The genotype distribution of nt -443 in the OPN promoter by gastric cancer TNM stage
The TNM stages of gastric cancer
Genotypes IA + IB IV P II IV P III IV P IA + IB + II + III IV P
-443
TT 32 29 1.00 5 29 1.00 19 29 1.00 56 29 1.00
CT 36 19 0.16 19 19 < 0.01* 19 19 0.33 74 19 0.04*
CC 3 14 0.011* 1 14 0.98 4 14 0.18 8 14 0.012*
* indicates significant difference (P < 0.05).
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stages (IA + IB + II + III; P = 0.012; Table 4). There were
no significant differences among the TNM stages and
the other two SNPs (nt -66 and nt -156) of the OPN
promoter. We also found no association between the
SNPs in the OPN promoter and lymph node metastasis.
Associations between genotypes in the OPN promoter
region and survival
Kaplan-Meier estimates of different genotypes at nt -443
in the OPN promoter are shown in Figure 2. The survival
rates for patients with the C/C genotype were significantly
lower than the survival rates for patients with the other
two genotypes (C/T, T/T). There were no significant asso-
ciations between survival and genotypes at the other sites
(nt -156 and nt -66).
Effect of the -443 T→ C polymorphism on promoter
activity
To examine the effect of the -443 T → C promoter re-
gion polymorphism on transcription of the OPN gene,
we measured promoter activity with a Dual LuciferaseFigure 2 Kaplan-Meier survival is significantly lower in gastric cancer
genotypes at nt -443 in OPN promoter.Reporter Assay System and compared the activities of
the -443C and -443 T alleles using a transient transfec-
tion assay with the MKN28 and SGC-7901 cell lines. As
shown in Figure 3, significantly higher luciferase acti-
vities were generated with the pGL3-C construct com-
pared to the pGL3-T construct (P = 0.001 for MKN28;
P = 0.021 for SGC-7901).Discussion
Mounting evidence suggests that OPN plays a role in
the regulation of tumor metastasis and that OPN ex-
pression is particularly high in metastatic tumors [22].
OPN is overexpressed in cancers that have a high pro-
pensity for forming bone metastases. In bone metastases,
OPN is generally associated with the interface between
the carcinoma and the bone surface, and this appears to
be related to increased bone resorptive activity by osteo-
clasts [23]. Moreover, high OPN expression in the pri-
mary tumor is associated with early metastasis and poor
clinical outcome in human gastric cancer and other can-
cers [24-27].patients with the C/C genotype as compared to the other two
Figure 3 Effect of the -443 T→ C polymorphism on promoter activity. Significantly higher luciferase activities were generated by the
pGL3-C construct as compared with the pGL3-T construct (P = 0.001 for MKN28; P = 0.021 for SGC-7901).
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associated with NSCLC [19]. In the present study, we fo-
cused on the association of these SNPs with GC, and al-
though the distribution of genotypes in the OPN
promoter was not significantly different between GC
patients and healthy controls, there were significant dif-
ferences in the distribution of genotypes (CC) at nt -443
between patients with stage IV and stage I gastric cancer
(IA + IB) and between stage IV and the combined other
three stages of gastric cancer (IA + IB + II + III; Table 4).
The survival rates for patients with the C/C genotype
were significantly lower than the survival rates of the
other two genotypes (C/T, T/T; Figure 3). In addition,
significantly higher luciferase activities were generated
with the pGL3-C construct compared to the pGL3-T
construct. Reporter gene analysis has shown that the
haplotype -443C/-156 G/-66 T is associated with signifi-
cantly enhanced promoter activity compared to five
other allelic variants tested [28]. A recent study on me-
lanoma metastases found that those homozygous for
the -443C allele expressed significantly higher levels of
OPN mRNA compared to those that were either hetero-
zygous (CT) or homozygous for the -443 T allele [29].
Transcription factor c-Myb binds to the region of the
OPN promoter in an allele-specific manner and induces
enhanced activity of the -443C compared to the -443 T
OPN promoter [30]. Taken together, these data suggest
that the variation at nt -443 in the OPN promoter plays
a role in GC progression and metastasis, especially for
the CC genotype at nt -443 in the OPN promoter.
Whether the polymorphisms of OPN is related to ex-
pression of OPN in cancer patients remain unknown al-
though. Over-expression of OPN was found in gastric
cancer samples in a previous study [14]. Therefore,additional studies are needed to further elucidate this
finding.
In the present study, we found that the CT genotype
at nt -443 in the OPN promoter showed significant dif-
ferences between stage IV and stage II gastric cancer,
and also between stage IV and other stages of gastric
cancer (IA + IB + II + III), but not between stage IV and
stage III or stage I. The main reason for this may be due
to the limited number of patients in each subgroup. It is
also possible that the transcription factor c-Myb might
have enhanced the activity of the region of the OPN pro-
moter that contained the CC or CT genotypes, but not
the other genotype (i.e., TT) [29]. However, these hy-
potheses require further investigation in larger studies.
The present genomic findings in healthy controls were
not identical to previous findings among Japanese and
Italian control subjects [30,31]. Although previous
reports suggest that high OPN is expressed at high levels
in GC [17], we found no association between the geno-
types of the OPN promoter with the risk of GC. How-
ever, we have found ethnic differences in SNPs of several
host genes in GC patients [30,31]. Therefore, the present
findings may not apply to all populations. Nonetheless,
although there was no association between OPN SNPs
and GC gastric cancer susceptibility or severity in
Chinese patients, our findings do suggest that there is an
association with metastasis of GC.
Conclusion
In conclusion, this is the first study of OPN genetic
polymorphisms and the risk of GC in a Chinese popula-
tion. We have demonstrated that genetic polymorphisms
at -443 in the OPN promoter are associated with metas-
tasis and subsequent death of GC. Therefore, these
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outcome of GC patients. However, additional studies are
needed using a larger cohort of patients in order to con-
firm these findings.
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